261 related articles for article (PubMed ID: 21426503)
1. Uremic toxins and oral adsorbents.
Goto S; Yoshiya K; Kita T; Fujii H; Fukagawa M
Ther Apher Dial; 2011 Apr; 15(2):132-4. PubMed ID: 21426503
[TBL] [Abstract][Full Text] [Related]
2. Effects of the oral adsorbent AST-120 on tryptophan metabolism in uremic patients.
Tsubakihara Y; Takabatake Y; Oka K; Shoji T; Togawa M; Okada N; Takahito I; Imai E
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S38-41. PubMed ID: 12612950
[TBL] [Abstract][Full Text] [Related]
3. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients.
Niwa T; Nomura T; Sugiyama S; Miyazaki T; Tsukushi S; Tsutsui S
Kidney Int Suppl; 1997 Nov; 62():S23-8. PubMed ID: 9350673
[TBL] [Abstract][Full Text] [Related]
4. Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120.
Niwa T
Ther Apher Dial; 2011 Apr; 15(2):120-4. PubMed ID: 21426500
[TBL] [Abstract][Full Text] [Related]
5. Role of oxidative stress and indoxyl sulfate in progression of cardiovascular disease in chronic kidney disease.
Fujii H; Nakai K; Fukagawa M
Ther Apher Dial; 2011 Apr; 15(2):125-8. PubMed ID: 21426501
[TBL] [Abstract][Full Text] [Related]
6. [Effect of oral sorbent, AST-120, on serum concentration of indoxyl sulfate in uremic rats].
Niwa T; Yazawa T; Maeda K; Ise M; Sugano M; Kodama T; Uehara Y
Nihon Jinzo Gakkai Shi; 1990 Jun; 32(6):695-701. PubMed ID: 2120492
[TBL] [Abstract][Full Text] [Related]
7. Indoxyl sulfate and progression of renal failure: effects of a low-protein diet and oral sorbent on indoxyl sulfate production in uremic rats and undialyzed uremic patients.
Niwa T; Tsukushi S; Ise M; Miyazaki T; Tsubakihara Y; Owada A; Shiigai T
Miner Electrolyte Metab; 1997; 23(3-6):179-84. PubMed ID: 9387112
[TBL] [Abstract][Full Text] [Related]
8. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
9. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis.
Niwa T; Ise M
J Lab Clin Med; 1994 Jul; 124(1):96-104. PubMed ID: 8035108
[TBL] [Abstract][Full Text] [Related]
10. Effects of oral adsorbent on gene expression profile in uremic rat kidney: cDNA array analysis.
Aoyama I; Enomoto A; Niwa T
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S8-14. PubMed ID: 12612943
[TBL] [Abstract][Full Text] [Related]
11. Impact of the Oral Adsorbent AST-120 on Organ-Specific Accumulation of Uremic Toxins: LC-MS/MS and MS Imaging Techniques.
Sato E; Saigusa D; Mishima E; Uchida T; Miura D; Morikawa-Ichinose T; Kisu K; Sekimoto A; Saito R; Oe Y; Matsumoto Y; Tomioka Y; Mori T; Takahashi N; Sato H; Abe T; Niwa T; Ito S
Toxins (Basel); 2017 Dec; 10(1):. PubMed ID: 29283413
[TBL] [Abstract][Full Text] [Related]
12. Uremic toxicity of indoxyl sulfate.
Niwa T
Nagoya J Med Sci; 2010 Feb; 72(1-2):1-11. PubMed ID: 20229698
[TBL] [Abstract][Full Text] [Related]
13. Update of uremic toxin research by mass spectrometry.
Niwa T
Mass Spectrom Rev; 2011; 30(3):510-21. PubMed ID: 21328600
[TBL] [Abstract][Full Text] [Related]
14. [The uremic toxin, indoxyl sulfate, signifies cardio-renal risk and intestinal-renal relationship].
Kiss I
Orv Hetil; 2011 Oct; 152(43):1724-30. PubMed ID: 21983398
[TBL] [Abstract][Full Text] [Related]
15. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study.
Brandenburg VM; Schlieper G; Heussen N; Holzmann S; Busch B; Evenepoel P; Vanholder R; Meijers B; Meert N; Fassbender WJ; Floege J; Jahnen-Dechent W; Ketteler M
Nephrol Dial Transplant; 2010 Aug; 25(8):2672-9. PubMed ID: 20172849
[TBL] [Abstract][Full Text] [Related]
16. Targeting protein-bound uremic toxins in chronic kidney disease.
Niwa T
Expert Opin Ther Targets; 2013 Nov; 17(11):1287-301. PubMed ID: 23941498
[TBL] [Abstract][Full Text] [Related]
17. The Effect of Sevelamer on Serum Levels of Gut-Derived Uremic Toxins: Results from In Vitro Experiments and A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
Bennis Y; Cluet Y; Titeca-Beauport D; El Esper N; Ureña P; Bodeau S; Combe C; Dussol B; Fouque D; Choukroun G; Liabeuf S
Toxins (Basel); 2019 May; 11(5):. PubMed ID: 31109001
[TBL] [Abstract][Full Text] [Related]
18. An oral adsorbent, AST-120, suppresses oxidative stress in uremic rats.
Nakagawa N; Hasebe N; Sumitomo K; Fujino T; Fukuzawa J; Hirayama T; Kikuchi K
Am J Nephrol; 2006; 26(5):455-61. PubMed ID: 17057375
[TBL] [Abstract][Full Text] [Related]
19. Oral sorbent AST-120 increases renal NO synthesis in uremic rats.
Tumur Z; Niwa T
J Ren Nutr; 2008 Jan; 18(1):60-4. PubMed ID: 18089446
[TBL] [Abstract][Full Text] [Related]
20. Possible involvement of nuclear factor-kappaB inhibition in the renal protective effect of oral adsorbent AST-120 in a rat model of chronic renal failure.
Komiya T; Miura K; Tsukamoto J; Okamura M; Tamada S; Asai T; Tashiro K; Kuwabara N; Iwao H; Yoshikawa J
Int J Mol Med; 2004 Jan; 13(1):133-8. PubMed ID: 14654984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
